Published in Proc Natl Acad Sci U S A on June 08, 2009
A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biol (2013) 1.98
Translation drives mRNA quality control. Nat Struct Mol Biol (2012) 1.97
Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology. Chem Biol (2010) 1.83
Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124. Proc Natl Acad Sci U S A (2010) 1.64
Ataluren as an agent for therapeutic nonsense suppression. Annu Rev Med (2012) 1.24
Therapeutics based on stop codon readthrough. Annu Rev Genomics Hum Genet (2014) 1.23
Firefly luciferase in chemical biology: a compendium of inhibitors, mechanistic evaluation of chemotypes, and suggested use as a reporter. Chem Biol (2012) 1.14
Suppression of premature termination codons as a therapeutic approach. Crit Rev Biochem Mol Biol (2012) 1.13
Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. Hum Mol Genet (2012) 1.11
Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases. Wiley Interdiscip Rev RNA (2011) 1.08
Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am J Pathol (2011) 0.98
Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations. J Cell Biochem (2011) 0.94
Cystic fibrosis chronic rhinosinusitis: a comprehensive review. Am J Rhinol Allergy (2013) 0.83
Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay. Mol Pharm (2014) 0.83
Multiple target-specific molecular agents for detection and image analysis of breast cancer characteristics in mice. Curr Mol Med (2013) 0.82
Aminoglycoside-Induced Premature Stop Codon Read-Through of Mucopolysaccharidosis Type I Patient Q70X and W402X Mutations in Cultured Cells. JIMD Rep (2013) 0.78
Therapeutic suppression of premature termination codons: mechanisms and clinical considerations (review). Int J Mol Med (2014) 0.78
High throughput screening in duchenne muscular dystrophy: from drug discovery to functional genomics. Biology (Basel) (2014) 0.75
PTC124 targets genetic disorders caused by nonsense mutations. Nature (2007) 6.67
Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet (2008) 4.35
Characterization of chemical libraries for luciferase inhibitory activity. J Med Chem (2008) 2.53
PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci U S A (2008) 2.22
Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc Natl Acad Sci U S A (2009) 2.18
Matrix elasticity directs stem cell lineage specification. Cell (2006) 43.00
Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics (2004) 19.05
Myotubes differentiate optimally on substrates with tissue-like stiffness: pathological implications for soft or stiff microenvironments. J Cell Biol (2004) 7.38
PTC124 targets genetic disorders caused by nonsense mutations. Nature (2007) 6.67
Poly(A)-binding proteins: multifunctional scaffolds for the post-transcriptional control of gene expression. Genome Biol (2003) 4.45
The mechanism of myosin VI translocation and its load-induced anchoring. Cell (2004) 3.85
Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. Am J Physiol Heart Circ Physiol (2006) 3.78
Genome-wide analysis of mRNAs regulated by the nonsense-mediated and 5' to 3' mRNA decay pathways in yeast. Mol Cell (2003) 3.66
NMD: a multifaceted response to premature translational termination. Nat Rev Mol Cell Biol (2012) 3.64
A structural state of the myosin V motor without bound nucleotide. Nature (2003) 3.63
A faux 3'-UTR promotes aberrant termination and triggers nonsense-mediated mRNA decay. Nature (2004) 3.60
Three myosin V structures delineate essential features of chemo-mechanical transduction. EMBO J (2004) 3.21
Early nonsense: mRNA decay solves a translational problem. Nat Rev Mol Cell Biol (2006) 3.11
Role of the lever arm in the processive stepping of myosin V. Proc Natl Acad Sci U S A (2002) 2.86
Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol (2002) 2.76
The structure of the myosin VI motor reveals the mechanism of directionality reversal. Nature (2005) 2.50
A model of myosin V processivity. J Biol Chem (2004) 2.49
Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med (2008) 2.49
Myostatin activation in patients with advanced heart failure and after mechanical unloading. Eur J Heart Fail (2010) 2.40
A force-dependent state controls the coordination of processive myosin V. Proc Natl Acad Sci U S A (2005) 2.39
Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene. J Mol Med (Berl) (2002) 2.34
Translation factors promote the formation of two states of the closed-loop mRNP. Nature (2008) 2.31
Myosin VI steps via a hand-over-hand mechanism with its lever arm undergoing fluctuations when attached to actin. J Biol Chem (2004) 2.31
Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther (2008) 2.27
PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci U S A (2008) 2.22
Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol (2007) 2.16
Toeprint analysis of the positioning of translation apparatus components at initiation and termination codons of fungal mRNAs. Methods (2002) 2.04
Derepression of the Her-2 uORF is mediated by a novel post-transcriptional control mechanism in cancer cells. Genes Dev (2006) 2.02
Leaky termination at premature stop codons antagonizes nonsense-mediated mRNA decay in S. cerevisiae. RNA (2004) 2.02
GTP hydrolysis by eRF3 facilitates stop codon decoding during eukaryotic translation termination. Mol Cell Biol (2004) 1.87
Neovasculogenic therapy to augment perfusion and preserve viability in ischemic cardiomyopathy. Ann Thorac Surg (2006) 1.82
Identification of a human endonuclease complex reveals a link between tRNA splicing and pre-mRNA 3' end formation. Cell (2004) 1.80
Full-length myosin VI dimerizes and moves processively along actin filaments upon monomer clustering. Mol Cell (2006) 1.80
A newly discovered function for RNase L in regulating translation termination. Nat Struct Mol Biol (2005) 1.80
Ribosome occupancy of the yeast CPA1 upstream open reading frame termination codon modulates nonsense-mediated mRNA decay. Mol Cell (2005) 1.79
A flexible domain is essential for the large step size and processivity of myosin VI. Mol Cell (2005) 1.78
Discrimination between defects in elongation fidelity and termination efficiency provides mechanistic insights into translational readthrough. J Mol Biol (2005) 1.65
The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve (2013) 1.63
Nuclear mRNA surveillance. Curr Opin Cell Biol (2003) 1.56
The structural basis for the large powerstroke of myosin VI. Cell (2007) 1.56
Degradation of YRA1 Pre-mRNA in the cytoplasm requires translational repression, multiple modular intronic elements, Edc3p, and Mex67p. PLoS Biol (2010) 1.51
Global analysis of Pub1p targets reveals a coordinate control of gene expression through modulation of binding and stability. Mol Cell Biol (2005) 1.50
Kinetic characterization of the weak binding states of myosin V. Biochemistry (2002) 1.46
Myosin IIb is unconventionally conventional. J Biol Chem (2003) 1.45
Interhead distance measurements in myosin VI via SHRImP support a simplified hand-over-hand model. Biophys J (2005) 1.43
YRA1 autoregulation requires nuclear export and cytoplasmic Edc3p-mediated degradation of its pre-mRNA. Mol Cell (2007) 1.43
Myosin VI dimerization triggers an unfolding of a three-helix bundle in order to extend its reach. Mol Cell (2009) 1.42
Magnesium regulates ADP dissociation from myosin V. J Biol Chem (2004) 1.42
Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve (2014) 1.41
Association of yeast Upf1p with direct substrates of the NMD pathway. Proc Natl Acad Sci U S A (2007) 1.40
Kinetic mechanism of blebbistatin inhibition of nonmuscle myosin IIb. Biochemistry (2004) 1.40
Viral expression of insulin-like growth factor-I enhances muscle hypertrophy in resistance-trained rats. J Appl Physiol (1985) (2004) 1.40
Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J Mol Med (Berl) (2002) 1.40
The unique insert in myosin VI is a structural calcium-calmodulin binding site. Proc Natl Acad Sci U S A (2004) 1.38
Cargo binding induces dimerization of myosin VI. Proc Natl Acad Sci U S A (2009) 1.34
Positive and negative regulation of poly(A) nuclease. Mol Cell Biol (2004) 1.32
The unique insert at the end of the myosin VI motor is the sole determinant of directionality. Proc Natl Acad Sci U S A (2007) 1.30
Patterning, prestress, and peeling dynamics of myocytes. Biophys J (2004) 1.29
Functional role of loop 2 in myosin V. Biochemistry (2004) 1.29
Non-stop decay--a new mRNA surveillance pathway. Bioessays (2002) 1.28
Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model. J Mol Med (Berl) (2006) 1.28
Nonsense-containing mRNAs that accumulate in the absence of a functional nonsense-mediated mRNA decay pathway are destabilized rapidly upon its restitution. Mol Cell Biol (2003) 1.27
The human immunodeficiency virus type 1 ribosomal frameshifting site is an invariant sequence determinant and an important target for antiviral therapy. J Virol (2004) 1.27
Rescue of dystrophic skeletal muscle by PGC-1α involves a fast to slow fiber type shift in the mdx mouse. PLoS One (2012) 1.26
Eukaryotic ribosomal RNA determinants of aminoglycoside resistance and their role in translational fidelity. RNA (2007) 1.26
Distinct eRF3 requirements suggest alternate eRF1 conformations mediate peptide release during eukaryotic translation termination. Mol Cell (2008) 1.25
Age-related differences in lower-limb muscle cross-sectional area and torque production in boys with Duchenne muscular dystrophy. Arch Phys Med Rehabil (2010) 1.24
Ataluren as an agent for therapeutic nonsense suppression. Annu Rev Med (2012) 1.24
Therapeutics based on stop codon readthrough. Annu Rev Genomics Hum Genet (2014) 1.23
Myosin Va and myosin VI coordinate their steps while engaged in an in vitro tug of war during cargo transport. Proc Natl Acad Sci U S A (2011) 1.23
Myosin VI undergoes a 180 degrees power stroke implying an uncoupling of the front lever arm. Proc Natl Acad Sci U S A (2009) 1.23
Skeletal muscles of ambulant children with Duchenne muscular dystrophy: validation of multicenter study of evaluation with MR imaging and MR spectroscopy. Radiology (2013) 1.22
Tpa1p is part of an mRNP complex that influences translation termination, mRNA deadenylation, and mRNA turnover in Saccharomyces cerevisiae. Mol Cell Biol (2006) 1.22
Aminoglycosides as potential pharmacogenetic agents in the treatment of Hailey-Hailey disease. J Invest Dermatol (2006) 1.22
The use of fungal in vitro systems for studying translational regulation. Methods Enzymol (2007) 1.20
Stromal cell-derived factor and granulocyte-monocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy. J Thorac Cardiovasc Surg (2005) 1.20
Adhesion-contractile balance in myocyte differentiation. J Cell Sci (2004) 1.20
Unregulated smooth-muscle myosin in human intestinal neoplasia. Proc Natl Acad Sci U S A (2008) 1.20
Calcium functionally uncouples the heads of myosin VI. J Biol Chem (2003) 1.18
Transcription factor B contacts promoter DNA near the transcription start site of the archaeal transcription initiation complex. J Biol Chem (2003) 1.17
Depth of proteome issues: a yeast isotope-coded affinity tag reagent study. Mol Cell Proteomics (2004) 1.16
Nonsense-mediated mRNA decay maintains translational fidelity by limiting magnesium uptake. Genes Dev (2010) 1.15
Suppression of premature termination codons as a therapeutic approach. Crit Rev Biochem Mol Biol (2012) 1.13
Molecular extensibility of mini-dystrophins and a dystrophin rod construct. J Mol Biol (2005) 1.13
Mutation of smooth muscle myosin causes epithelial invasion and cystic expansion of the zebrafish intestine. Dev Cell (2005) 1.11
Identification of factors regulating poly(A) tail synthesis and maturation. Mol Cell Biol (2004) 1.11
Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression. PLoS One (2013) 1.11
Changes in inorganic phosphate and force production in human skeletal muscle after cast immobilization. J Appl Physiol (1985) (2004) 1.10
Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice. PLoS One (2010) 1.10
Rare, nonsynonymous variant in the smooth muscle-specific isoform of myosin heavy chain, MYH11, R247C, alters force generation in the aorta and phenotype of smooth muscle cells. Circ Res (2012) 1.10